|
Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia
|
|
Shardul Nautiyal, Mumbai
November 13 , 2026
|
|
|
India's pharmaceutical exporters have been offered a fresh business opportunity to expand their presence in Saudi Arabia, with Riyadh-based Al Hobail Medical Company seeking Indian manufacturing partners for the registration and commercialisation of a specified portfolio of pharmaceutical products in the Kingdom.
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has invited its member companies with matching product portfolios and requisite regulatory documentation to explore the proposed collaboration, which could provide an avenue for Indian manufacturers to access Saudi Arabia's institutional procurement system and private pharmaceutical distribution market.
According to a business expression of interest received by Pharmexcil from Al Hobail Medical Company, the Saudi company is looking to identify Indian pharmaceutical manufacturers capable of supplying products from a specific list of requirements for registration and subsequent commercialisation in the Saudi Arabian market. The detailed product requirement list has been circulated among Pharmexcil members to enable companies to assess their product portfolios and identify potential areas of collaboration.
Under the proposed business arrangement, the selected pharmaceutical products would be registered in Saudi Arabia with Al Hobail Pharmaceuticals acting as the Marketing Authorisation Holder (MAH). Following regulatory registration, the products would be commercialised through multiple distribution and procurement channels, including the National Unified Procurement Company (NUPCO), the Saudi Ministry of Health (MOH), and private healthcare institutions and pharmaceutical distribution networks.
The proposed arrangement is significant for Indian pharmaceutical exporters seeking to strengthen their presence in the Middle East, particularly through partnerships that combine Indian manufacturing capabilities with an established local marketing and distribution framework. Access to government procurement channels, alongside private healthcare distribution, could create opportunities for Indian manufacturers to diversify their export markets and build a commercial presence in Saudi Arabia.
However, participation in the proposed opportunity will depend on manufacturers' ability to meet the applicable regulatory and documentation requirements. Interested companies are expected to have completed or submission-ready Common Technical Document (CTD) or electronic Common Technical Document (eCTD) dossiers, valid Good Manufacturing Practice (GMP) certificates and Certificates of Pharmaceutical Product (COPP), along with valid manufacturing licences and product permissions.
Manufacturers should also possess Zone IVb stability data to support product registration under the climatic conditions relevant to the Saudi market. Bioequivalence (BE) study reports will be required wherever applicable, depending on the nature of the pharmaceutical products and regulatory requirements.
Pharmexcil Director General (DG) K Raja Bhanu said the council has received the expression of interest from Al Hobail Medical Company and is facilitating the communication of this business opportunity to its member companies. He encouraged eligible Indian pharmaceutical manufacturers with matching product portfolios and the necessary regulatory documentation to communicate their interest directly to the Saudi company and explore the proposed collaboration.
As part of the expression of interest process, participating companies are required to submit their corporate profile, details of manufacturing facilities, a list of products matching Al Hobail's requirements and information on the availability of regulatory documentation for each proposed product. They must also provide the name and contact details of an authorised representative to facilitate further commercial and regulatory discussions.
Interested manufacturers have been asked to submit their proposals directly to Mohammed Sadiq Ahmed, tender manager, Al Hobail Medical Company. Pharmexcil has advised its members to communicate their interest at the earliest to enable direct coordination with Al Hobail Medical Company and facilitate discussions on potential product registration and commercialisation partnerships.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|